Universal Registration Document News Today

Iqirvo® (elafibranor) 80 mg tablets is the first new medicine approved in nearly a decade for the treatment of the rare liver

FY24 RESULTS Paris | May 23rd, 2024 DISCLAIMER ...

Sommaire : 2023 - A year of resilience 2023 - An ESG strategy integral to the corporate p... ...

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced members of its executive team are scheduled to participate in the upcoming conferences

PRESS RELEASE Arcueil, May 27, 2024 2024 first-half results Acceleration of profitable growth: +26% in volumes and sharp...

Top line results of TELLOMAK Phase 2 trial in mycosis fungoides confirming promising clinical activity of lacutamab Two posters on IPH6501, Innate's second generation ANKET, for the treatment

FY24 RESULTS Paris | May 23rd, 2024 DISCLAIMER ...

Answers to the written questions 2024 of the Forum pour lInvestissement Responsable This document is a free translation for convenience...

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced the voting results of its shareholders at the Annual General Meeting ("AGM"), which took

OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases Nantes,...